# A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

> **NCT02374489** · PHASE2 · TERMINATED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 9 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** LDK378

## Key facts

- **NCT ID:** NCT02374489
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** ROS1 in IHC and gene rearrangement result can not match。No tumor response。
- **Last updated:** 2018-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02374489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02374489, "A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02374489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*